TRexBio is a biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology. Our Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio was founded and seed funded by SV Health Investors in 2018 and is headquartered in South San Francisco, California. TRexBio was one of the first companies in residence at Lilly Gateway Labs, a shared innovation space where Eli Lilly and Company enables and engages high-caliber, early-stage biotechs to do break-through science.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/13/24 | $84,000,000 | Series B |
Agent Capital Alexandria Venture Investments Avego Bioscience Capital Delos Capital  Eli Lilly and Company Johnson & Johnson Development Corporation (JJDC) Pfizer Venture Investments Polaris Partners SV Health Investors | undisclosed |
